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Abstract
Introduction: This paper reviews recent trends in the production, supply and price of the active
ingredients as well as finished ACT products. Production and cost data provided in this paper are
based on an ongoing project (Artepal). Stability data are derived from a development project on
rectal artesunate.
Discussion: The artemisinin raw material and its derivatives appear to be very stable compared
to the finished products. Supply of artemisinin changed in May 2004 when the Global Fund shifted
financial support to qualified countries from chloroquine or sulphadoxine-pyrimethamine to an
ACT for treatment of malaria. First, there was a sudden shortage of the starting material, and short
term scarcity led to a steep rise in API price: it increased dramatically in 2004, from $350 per kg
to more than $1000. Second, there was a parallel increase in the number of companies extracting
artemisinin from 10 to 80 between 2003 and 2005 in China, and from 3 to 20 in Vietnam.
Commercial cultivation began also in East Africa and Madagascar.
A steady and predictable demand for the crop can eliminate such wide fluctuations and indirectly
contribute to price stability of the herb, the API and ACT. With appropriate mechanisms to reduce
those fluctuations, the cost of artemisinin might decrease sustainably to US$ 250–300 per kg.
Conclusion: Today the global health community is facing the risk of another cyclical swing with
lower demand feeding into reduced planting of A. annua and, thereafter, a new shortage of the raw
material and higher API prices. International donors, the largest purchasers for ACTs could better
coordinate their activities, in order to guarantee purchase of ACTs and consequently of API with
manufacturers. In parallel, the base of quality producers of APIs and finished ACT products needs
to be broadened.
While the ACT programme is still in its early stages, the consequences of another wave of 
artemisinin and ACT shortages would permanently discredit it and impede any progress in rolling 
malaria back.
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Introduction
Artemisinin compounds, derived from Artemisia annua,
also known as sweet wormwood, have become the corner-
stone of malaria case-management whether used orally
for the treatment of uncomplicated malaria episodes or in
parenteral or rectal administration for severe malaria. The
World Health Organization (WHO) now recommends
treating uncomplicated malaria with artemisinin-based
combinations therapies (ACTs) [1]. This new policy was
issued to protect the artemisinins and the partner drug
from resistance in the wake of reduced efficacy of the well-
known once-first-line, antimalarials (chloroquine, and
sulphadoxine-pyrimethamine) due to resistance. ACTs are
much more expensive and have a shorter shelf-life than
the traditional antimalarials. They consequently require
substantially improved post-production supply-chain
support in malaria endemic countries.
WHO's guidance on ACTs first issued in 2001 has just
been re-stated with evidence justifying the recommenda-
tions [2], but the uptake of ACT continues to be low
despite increased donor funding.
This paper reviews recent trends in the production, supply
and price of the active ingredients as well as finished ACT
products, and identifies factors that need to be taken into
account in stabilizing the artemisinin market and lower-
ing the price of ACTs to achieve wider use of these impor-
tant medicines.
Production and cost data provided in this paper are based
on field visits, interviews, and indirect verification under-
taken in the course of an ongoing project (Artepal) that
seeks to facilitate transfer of ACT technology to Africa and
Asia, keep producers and potential clients informed about
global artemisinin production and consumption, and
provide public information regarding difficulties produc-
ers are facing (see website http://www.artepal.org). Stabil-
ity data are derived from an ongoing development project
on rectal artesunate.
Discussion
From Artemisia annua to ACT
(i) A.annua cultivation and production of artemisinin
The world's production of Artemisia annua is, at present,
dominated by cultivation in East Asia (mainly China and
Vietnam) with recent additions of crop in East and South-
ern Africa, including Madagascar.
Harvesting of A. annua takes place before flowering when
the artemisinin yield is highest, and is completed within a
month. Extraction takes place during four to six months
after the harvest which occurs around six months after
planting. Thus a period of 12 months from the time of
planting of A. annua is required to first produce the bulk
artemisinin starting material and eventually the finished
product.
The average yield of A. annua varies between 1.5 to 2 tons
of dried matter per hectare and the average content of
artemisinin varies with the seed quality, climate, altitude,
soil, farmers know-know, and planting density. In gen-
eral, it lies between 0.5–1.2%, while extraction and puri-
fication yield are in the range of 50–80%. These
parameters may change with time as cultivation methods
further improve [3], but their present value lead to pro-
ducing from 6 to 14 kgs of artemisinin raw material per
hectare.
In order to bypass the bottleneck associated with plant
production, investments are being made to obtain substi-
tutes sharing the same trioxane active moiety of artemisi-
nin by total synthesis; one such molecule is currently in
clinical development. However, plant production of A.
annua will remain indispensable to the ACT programme
for the foreseeable future.
(ii) Production and stability of the active pharmaceutical ingredient 
(API)
The artemisinin "raw" or "starting material" extracted
from the dried plant is transformed into artemisinin
based APIs produced through further hemi-synthesis of
artemisinin. Transformation of artemisinin into any one
of these APIs – dihydroartemisinin (DHA), artesunate
(AS), artemether (AM) or arteether (AE) – requires indus-
trial facilities and further manufacturing.
The active pharmaceutical ingredient proves to be stable
for all the APIs for which we have data. Table 1 shows sta-
bility data for most of the artemisinin derivatives – artem-
isinin, dihydroartemisinin and artesunate, expressed in
percentage of API content. Data were provided by Abbott/
Knoll for artesunate and IPCA for artemisinin and dihy-
droartemisinin, then consolidated by WHO/TDR (Tropi-
cal Disease Research).
The bulk drug substance is seen to be very stable at tem-
peratures of 30°C and 65% relative humidity (RH), con-
ditions required for stability testing for climatic zones III
(hot and dry) and IV (hot and humid). Data are available
for three years for API stored at 30°C and RH of 70% and
for five years for API of artesunate stored at 25°C and RH
60%. Data are not available for artemether.
No term tests of stability longer than 60 months have so
far been conducted for these APIs.
(iii) Production and stability of the final finished product – ACT
ACTs are currently provided either as two independently-
formulated and co-blistered products (the artemisininMalaria Journal 2007, 6:125 http://www.malariajournal.com/content/6/1/125
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component and the companion drug), or as fixed-dose
co-formulations. The development of the final pharma-
ceutical dosage form in ACTs is complicated by the fact
that there are two active ingredients, i.e. two APIs each
requiring independent production and final formulation
as a fixed-dose combination with compatible excipient
(s).
The shelf-life specified by regulatory authorities for the
final ACT dosage forms is much shorter than that of the
API. No stringent regulatory agency has approved a shelf-
life that exceed 24 months for any oral formulations of
artemisinin-based combinations.
Factors affecting ACT availability
(i) Supply of artemisinin
Initially, artemisinin-based products were manufactured
and used almost exclusively in China and Vietnam. Dur-
ing this period, it was not difficult for agricultural produc-
tion to meet stable domestic or regional requirements.
The situation changed in May 2004 when the Global Fund
for AIDS, Tuberculosis and Malaria (GFATM) shifted
financial support to qualified countries from chloroquine
or sulphadoxine-pyrimethamine therapy to an ACT for
treatment of malaria. At the time, the WHO estimated the
ACT demand to be 10 million treatment courses for 2004
and 60 million for 2005 [4]. The announcement that the
GFATM would shift funding support to ACTs by $200 mil-
lion in the wake of an intense exchange between the
GFATM and proponents of combination therapy [5], had
two consequences, not fully anticipated at the time, which
are illustrated on Figure 1.
First, there was a sudden shortage of the starting material,
and short term scarcity led to a steep rise in API price
about which more is said below. At the time the GFATM
resolution was made, farmers had already made decisions
regarding the total area they would plant to different
crops, including A. annua, on the basis of past market
prices for artemisinin versus other commercial crops. The
emerging shortage was widely reported and a likely
increase in production forecast [6].
Second, propelled by the prospect of increased prices, the
total acreage devoted to plantations of A. annua indeed
increased substantially in China and Vietnam in the
December 2005 planting season, the farmers now reacting
to the 2005 reality and prospect of higher prices in 2006.
There was a parallel increase in the number of companies
extracting artemisinin from 10 to 80 between 2003 and
2005 in China, and from 3 to 20 during the same period
in Vietnam. Commercial cultivation began in East Africa
and Madagascar.
Afterwards, with 2006 reductions in price of the API and
uncertainty about future demand for the artemisinin API,
factors discussed in sections that follow, the rate of new
planting has begun to fall and a fall is predicted for 2007.
areas planted to A.annua and output of artemisinin from 2003  to 2006, with 2007 projections Figure 1
areas planted to A.annua and output of artemisinin from 2003 
to 2006, with 2007 projections.
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Table 1: Stability data of artemisinin derivatives, in percentage of API content.
Product and 
conditions
Specification 12 months 24 months 36 months 48 months 60 months
Artemisinin 
30°C RH 65%
99,0% 99,6% 100,0% 99,6% not tested not tested
Dihydroartemisi
nin 30°C, RH 
65%
98%–102% 99,2% 99,4% 99,8% 99,7% not tested
Artesunate 
25°C RH 60%
98–102% 99,5% 100,5% 99,1% 99,6% 99,8%
Artesunate 
30°C RH 70%
98–102% 101,3% 101,4% 100,8% not tested not testedMalaria Journal 2007, 6:125 http://www.malariajournal.com/content/6/1/125
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Figure 1 provides data from the Artepal project on esti-
mated area planted (in hectares with log scale) to A.annua
from 2003 to 2006, and the output of artemisinin (in met-
ric tons) during the period 2003 to 2006, with 2007 pro-
jections.
(ii) The market for A. annua, artemisinin and the packaged product
The demand for A. annua derives from the demand for the
finished formulated product by customers and purchasers
(health services and individuals in malaria-endemic coun-
tries, international organizations). The price of the prod-
uct plays a role at all levels. The supplementary cost of
ACTs compared with chloroquine has meant that many
health services in these countries depend on donor sup-
port for ACT procurement. Like malaria patients and
health services, donors themselves have an interest in see-
ing the prices of ACT as low as possible to ensure that
available budgets can reach the largest number possible of
malaria patients.
Any increase in the price of artemisinin – in turn depend-
ing on the price of A. annua – contributes to the ultimate
cost of ACT and is, therefore, of major concern to policy
and practice. The API price of the artemisinin component
typically accounts for 20 to 40 per cent of the final price of
the finished ACT product, depending on the companion
drug in the ACT [7].
The supply of A. annua plays an equally important role.
For a given level of demand by product manufacturers, a
greater supply of the herb contributes to lowering its price
while a temporary shortage can drive up its price and
those of artemisinin final product. Not unlike other non-
regulated commercial crops, demand fluctuations can set
off a cycle of supply adjustments and price volatility as
producers adjust the area planted on the basis of their
price expectations. A year of abundance of the raw mate-
rial can quickly turn into a year of relative scarcity as hap-
pened recently. A steady and predictable demand for the
crop can eliminate such wide fluctuations and indirectly
contribute to price stability of the herb, the API and ACT.
Other factors such as the increased yield of A. annua due
to agronomical improvements or the efficiency of the API
extraction process can, in favourable circumstances, per-
manently lower the price of both the crop and the API.
(iii) Demand for ACTs
How much is at stake? The upper limit to the demand for
ACT treatment would be given by the simple number of
malaria sufferers (times the appropriate dose in each
case), a point that might be reached if ACT were to be dis-
tributed free of charge and at the right moment. Current
global and country estimates of the upper limit ("the
need", to the medical profession) vary greatly and are not
particularly reliable given generally inaccurate country
reporting and a widespread practice of treating many
fevers (rather than only parasitologically-confirmed
malaria) with antimalarials. Available estimates include
2.84 billion fever episodes per annum in Africa [8] and a
range of estimates of falciparum clinical malaria cases from
226 million [9] to 365 (215–374 million) [10]. Using a
consumption method with old antimalarials, the pro-
jected lower and upper number of adult treatments was
estimated at 113–314.5 million equivalent adult treat-
ments for the continent [11].
The above figures can be compared to the number of
actual recorded orders for ACT treatments by the public
sector mostly by the Global Fund (Figure 2), showing that
the continent's current consumption of ACT falls well
short of the medical need.
(iv) Trends in artemisinin prices
The prices of artemisinin API during the last three years
increased dramatically in 2004, from $350 per kg to more
than $1,000. This trend was confirmed by other sources
[6].
Such fluctuations are striking but the pattern is not sur-
prising. The peak of prices occurred in 2004 (stimulated
by official support given to ACT by WHO), before addi-
tional output from extra planting of 2005 and 2006 could
materialize. The rapid drop in prices of 2006 appears to
reflect the major increase in production in 2006, a year
that saw orders stay below 100 million treatments, con-
trary to earlier expectations and predictions. Prices have
decreased to US$ 250 per kg at the end of 2006 and first
half of 2007 (with spot prices under US$ 200). Hectarage
planted in late 2006–2007 has likely reverted to its previ-
recorded orders of ACTs by the public sector (courtesy of  Marise Dugue, WHO/GMP), and market prices of bulk  artemisinin for small orders (Artepal project) Figure 2
recorded orders of ACTs by the public sector (courtesy of 
Marise Dugue, WHO/GMP), and market prices of bulk 
artemisinin for small orders (Artepal project).
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ous low base. In the presence of mechanisms that reduce
wide demand fluctuations – one of which might be a sys-
tem of guaranteed purchases – the cost of artemisinin
might decrease sustainably to US$ 250–300 per kg.
Conclusion
High prices and temporary artemisinin shortages such as
those experienced in 2004/2005 are a serious threat to the
ACT programme. High and unstable API prices have a
negative impact on ACT affordability and have been a psy-
chological factor undermining confidence in ACT availa-
bility and affordability in the future.
As this article is going to press (third quarter of 2007),
there is a glut of artemisinin and a number of artemisinin
producers (in China, for instance) have announced plans
to reduce or discontinue production. The global health
community is facing the risk of another cyclical swing
with lower demand feeding into reduced planting of A.
annua and, thereafter, a new shortage of the raw material
and higher API prices. The market for artemisinin is not
mature and in the absence of demand-stabilizing factors
the periodic fluctuations are likely to undermine faith in
the direction of the malaria treatment advocated by WHO
in spite of increased funding for ACT. For this to be
avoided, several things need to happen.
First, market demand needs to be stabilized. ACT pur-
chases are special in the sense of being dominated by a rel-
atively small number of donor organizations. The
majority of individual country orders are made via sub-
missions to the Global Fund (sometimes via WHO), as
well as through procurement by organizations such as the
President Malaria Initiative or the World Bank. These
organisations – the largest purchasers for ACTs by far –
could better coordinate their activities, in order to guaran-
tee purchase of ACTs and consequently of API to manufac-
turers, thus mitigating market instability and obtaining
the lowest possible prices. For now, the donor community
purchasing ACTs does not send coordinated or consistent
messages to producers, either those of the API or of the
finished product. By default, the market is determined
largely by the main manufacturers of finished products via
their forward contracts with artemisinin producers
designed to secure the raw material for their own prod-
ucts. An opportunity to bring about more stable prices of
the raw material for everybody and lower the prices of
artemisinin API is lost.
Such a coordination would include consolidation of glo-
bal orders and better frameworks regarding contract agree-
ments (as happens, for instance, in vaccine procurement).
The aim should be steady (and possibly guaranteed)
prices for bulk raw material which must also be fair to the
producers and farmers.
In the meanwhile, the relatively long stability of the APIs
could also be used to moderate short-term API price fluc-
tuations by developing a mechanism for guaranteed pur-
chases.
Second, and in parallel, the base of quality producers of
APIs and finished ACT products needs to be broadened.
This is key to improving the availability of GMP produc-
tion and increasing competition among the API and ACT
producers (and thus minimizing unnecessary price
increases). Subsidizing costs of meeting the international
criteria and gaining WHO certification might be consid-
ered, for instance, for those companies unable to invest in
costly bio-equivalence studies, generally necessary for pre-
qualification and access to public sector bidding.
While these are the two main requirements emerging
from this analysis, it is clear that in order for ACTs to be
successfully implemented, other conditions should also
be met. ACTs are an expensive product with a relatively
short shelf life, and need to be ordered and used in time.
Shortening the lag from production to use through a more
effective supply and distribution chain support in malaria
endemic countries is an essential long-term policy objec-
tive.
The comparatively short shelf life of the final product is
also a critical consideration as manufacturers risk overpro-
duction.
Progress on the above issues is a matter of some urgency
requiring concrete public action. While the ACT pro-
gramme is still in its early stages, the consequences of
another wave of artemisinin and ACT shortages would
permanently discredit it and impede any progress in roll-
ing malaria back.
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